RecruitingPhase 2ACTRN12607000604404

A study looking at the effect positron emission tomography (PET) scans have on the treatment decisions specialists make in patients with suspected cancer of the pancreas.

A prospective study investigating the impact of the addition of FDG-PET/CT on treatment decisions compared to standard pre-operative work up for patients with suspected pancreatic, peri-ampullary or bile duct malignancies


Sponsor

Royal Brisbane Hospital

Enrollment

90 participants

Start Date

Jan 15, 2008

Study Type

Interventional

Conditions

Summary

In addition to the standard pre-operative investigations you will also undergo a PET scan. Your results will be compared to people who only receive the routine pre-operative investigations, to see if the use of the PET scan changes the treatment plan. A PET scan is a non-invasive nuclear imaging test. In other cancers, particularly lung cancer, this scan can detect the spread of cancer better than other tests. If you have a suspected pancreatic cancer, the usual tests might include a CT (computed tomography) scan, ultrasound, MRI (magnetic resonance imaging) scan and an ERCP (endoscopic retrograde cholangiopancreatography). If a PET scan helps show the extent of the cancer better, your diagnosis will be more accurate and this might spare you unnecessary major surgery.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria5

  • Suspected or proven localized pancreatic, ampullary or bile duct malignancy on the basis of standard investigations;
  • = 18 years old;
  • Deemed suitable, based on tumour stage and medical fitness, to potentially undergo surgery or radiotherapy with curative intent;
  • Available for follow up for at least 12 months from the date of PET/CT scanning;
  • Able to provide Informed Consent.

Exclusion Criteria6

  • Claustrophobia;
  • Uncontrolled diabetes mellitus;
  • Pregnancy;
  • Unable to provide informed consent;
  • Inability to undergo PET/CT study;
  • Any disease, condition, physical examination finding or clinical laboratory finding which, in the opinion of the investigator, makes the patient inappropriate for the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Adding 18 fluorodeoxyglucose positron emission tomography (FDG-PET) which,in other cancers, is better able to pick up cancer spread than other tests are. This scan will be done once at the time of dia

Adding 18 fluorodeoxyglucose positron emission tomography (FDG-PET) which,in other cancers, is better able to pick up cancer spread than other tests are. This scan will be done once at the time of diagnosis and staging.


Locations(1)

QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000604404